| Ruth M Spillerman, MD | |
|
2240 Ridgewood Rd, Ste 100, Wyomissing, PA 19610-1167 | |
| (610) 376-8691 | |
| (610) 376-8745 |
| Full Name | Ruth M Spillerman |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 2240 Ridgewood Rd, Wyomissing, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578567566 | NPI | - | NPPES |
| 1748704 | Medicaid | PA | |
| 06032A | Other | PA | EPSDT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD068268L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ruth M Spillerman, MD 2240 Ridgewood Rd, Ste 100, Wyomissing, PA 19610-1167 Ph: (610) 376-8691 | Ruth M Spillerman, MD 2240 Ridgewood Rd, Ste 100, Wyomissing, PA 19610-1167 Ph: (610) 376-8691 |
News Archive
University of Michigan researchers have proven that a special surface, free of biological contaminants, allows adult-derived stem cells to thrive and transform into multiple cell types. Their success brings stem cell therapies another step closer.
Cadence Pharmaceuticals, Inc. today announced that it has priced an underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $8.00 per share. The net proceeds from the sale of the shares, after estimated underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $86.2 million.
Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.
Researchers from the Boston University School of Medicine (BUSM) have determined how the TGFβ-Smad signaling pathway, which is over activated in late-stage cancers, is responsible for the "epigenetic memory" that maintains unique patterns of regulatory DNA hypermethylation causing silencing of critical genes that facilitate breast cancer progression.
Older drivers can see their driving abilities improve by participating in certain types of training that improves the brain's processing speed and how the mind reacts when attention is divided, according to a new study by a researcher from the University of South Florida and colleagues from several other universities.
› Verified 3 days ago
Tiffany L. Sergi, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 40 Berkshire Ct, Wyomissing, PA 19610 Phone: 610-374-7400 Fax: 610-374-4252 | |
Joe K. George, D.O. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 40 Berkshire Ct, Suite 1, Wyomissing, PA 19610 Phone: 610-374-7400 Fax: 610-374-4252 | |
Robert J Cordes, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2240 Ridgewood Rd, Ste 100, Wyomissing, PA 19610 Phone: 610-376-8691 Fax: 610-376-8745 | |
Sanand R. Menon, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 40 Berkshire Ct, Wyomissing, PA 19610 Phone: 610-374-7400 Fax: 610-374-4252 | |
Amanda Lynn Gosling, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 40 Berkshire Ct, Suite 1, Wyomissing, PA 19610 Phone: 610-374-7400 Fax: 610-374-1641 | |
Jennifer L Watson, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 40 Berkshire Ct, Suite 1, Wyomissing, PA 19610 Phone: 610-374-7400 Fax: 610-374-1641 | |
Mark S. Reuben, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 40 Berkshire Ct, Wyomissing, PA 19610 Phone: 610-374-7400 Fax: 610-374-1641 |